New combo therapy targets tough stomach cancer
Disease control
Completed
This study tested a new combination of two drugs, GEN-001 and avelumab, in 42 people with advanced stomach or gastroesophageal junction cancer that had not responded to at least two prior treatments. The goal was to see if the combination could shrink tumors or slow cancer growth…
Phase: PHASE2 • Sponsor: Genome & Company • Aim: Disease control
Last updated May 11, 2026 20:52 UTC